Opinion|Videos|November 12, 2024
Advances in Menopause Treatment: A Focus on the Neurokinin Pathway
Key Takeaways
- Neurokinin is crucial in the pathophysiology of vasomotor symptoms linked to menopause, offering a target for novel treatments.
- Fezolinetant, a nonhormonal agent, antagonizes neurokinin-3 receptors to treat moderate to severe VMS.
Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (PINKERTON) What is the role of neurokinin in the pathophysiology of vasomotor symptoms?
- (SMITH) Fezolinetant is a nonhormonal novel agent now available for the treatment of moderate to severe VMS due to menopause. How is moderate to severe VMS defined? What is the mechanism of action of fezolinetant?
- (PINKERTON) Elinzanetant is another nonhormonal, novel agent recently submitted for FDA approval for the treatment of moderate to severe VMS. What is the mechanism of action of elinzanetant, and how might the unique mechanism of NK1 antagonism help to treat other menopause-related conditions, such as mood disturbances or sleep disorders?
- (FIFFICK) What are the advantages of targeting the neurokinin pathways in menopause treatment compared with traditional hormonal approaches?
Advertisement
Related to this article
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
5